News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

In Bid For Allergan Inc. (AGN), Valeant Pharmaceuticals International (VRX) Defends Its Record On Research


6/12/2014 5:56:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

As it pursues a hostile takeover of Allergan, Valeant has reiterated time and again its belief that most pharmaceutical research and development doesn’t pay off.

Seeking to defend itself, Allergan has seized on those comments, accusing Valeant of being more concerned with financial engineering than with innovation. Formally rejecting Valeant’s latest offer on Tuesday with a news release and slide show, Allergan trumpeted its own research successes while pillorying Valeant’s approach.

Help employers find you! Check out all the jobs and post your resume.

Read at New York Times

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES